利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.027 秒)

    Angiogenically effective unit dose fo FGF and method of adminstering
    1.
    发明申请
    Angiogenically effective unit dose fo FGF and method of adminstering 有权
    FGF的血管生成有效单位剂量和施用方法

    公开(公告)号：US20060025343A1

    公开(公告)日：2006-02-02

    申请号：US11238936

    申请日：2005-09-29

    申请人： Martha Whitehouse ,  W. Kavanaugh

    发明人： Martha Whitehouse ,  W. Kavanaugh

    IPC分类号： A61K38/18

    CPC分类号： A61K38/1825

    摘要： The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 μg/kg to 36 μg/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof. In yet another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.

    摘要翻译： 本发明具有多个方面。 特别地，一方面，本发明涉及包含0.2μg/ kg至36mug / kg重组FGF或其血管生成活性片段或突变蛋白的单位剂量。 在另一方面，本发明涉及包含血管生成有效剂量的FGF或其血管生成活性片段或突变蛋白和药学上可接受的载体的药物组合物。 通常，血管生成有效剂量包含0.2μg/ kg至36mug / kg SEQ ID NO：1-3,5,8-10或12-14中任一项的FGF或其血管生成活性片段或突变蛋白。 另一方面，本发明涉及用于治疗冠状动脉疾病的人类患者的方法，包括对需要治疗冠状动脉疾病的人类患者的至少一个冠状血管施用安全和血管生成有效剂量的 SEQ ID NO：1-3,5,8-10或12-14中任一项的重组FGF或其血管生成活性片段或突变蛋白。

    Angiogenically effective unit dose of FGF-2 and method of use
    3.
    发明申请
    Angiogenically effective unit dose of FGF-2 and method of use 失效
    FGF-2的血管生成有效单位剂量及其使用方法

    公开(公告)号：US20070142283A1

    公开(公告)日：2007-06-21

    申请号：US11511028

    申请日：2006-08-28

    申请人： Martha Whitehouse

    发明人： Martha Whitehouse

    IPC分类号： A61K38/18 ,  A61K31/727

    CPC分类号： A61K31/727 ,  A61K38/1825 ,  A61K2300/00

    摘要： The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts 2 months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.

    摘要翻译： 本发明具有多个方面。 特别地，在一个方面，本发明涉及包含0.2μg/ kg至48μg/ kg的SEQ ID NO：2的FGF-2或其药学上可接受的血管生成活性片段或突变蛋白的单位剂量组合物 可接受的载体 另一方面，本发明涉及一种治疗冠状动脉疾病的人类患者的方法，其包括对需要治疗冠状动脉疾病的人类患者的一个或多个冠状动脉血管或外周静脉施用安全和血管生成 有效剂量的重组FGF-2或其血管生成活性片段或突变蛋白。 本发明的单一单位剂量组合物在需要再治疗的2个月内在人CAD患者中提供血管生成作用。 另一方面，本发明涉及优化患者安全性的给药方法。 在该实施方案中，流体，肝素和/或输注速率都起作用。 在另一方面，本发明涉及药物组合物，其在治疗有效的载体中包含治疗有效量的单独或与肝素组合的FGF-2。 效益的幅度和持续时间是意想不到的; 另外有利于IV路线是意想不到的。

    Angiogenically effective unit dose of FGF-2 and method of use
    4.
    发明申请
    Angiogenically effective unit dose of FGF-2 and method of use 有权
    血管生成有效单位剂量的FGF-2及其使用方法

    公开(公告)号：US20050143298A1

    公开(公告)日：2005-06-30

    申请号：US10862152

    申请日：2004-06-04

    申请人： Martha Whitehouse

    发明人： Martha Whitehouse

    IPC分类号： A61K38/22 ,  A61K38/00 ,  A61K38/18 ,  A61P9/00 ,  A61P9/10 ,  A61K31/727

    CPC分类号： A61K31/727 ,  A61K38/1825 ,  A61K2300/00

    摘要： The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts 2 months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.

    摘要翻译： 本发明具有多个方面。 特别地，在一个方面，本发明涉及包含0.2μg/ kg至48μg/ kg的SEQ ID NO：2的FGF-2或其药学上可接受的血管生成活性片段或突变蛋白的单位剂量组合物 可接受的载体 另一方面，本发明涉及一种治疗冠状动脉疾病的人类患者的方法，其包括对需要治疗冠状动脉疾病的人类患者的一个或多个冠状动脉血管或外周静脉施用安全和血管生成 有效剂量的重组FGF-2或其血管生成活性片段或突变蛋白。 本发明的单一单位剂量组合物在需要再治疗的2个月内在人CAD患者中提供血管生成作用。 另一方面，本发明涉及优化患者安全性的给药方法。 在该实施方案中，流体，肝素和/或输注速率都起作用。 在另一方面，本发明涉及药物组合物，其在治疗有效的载体中包含治疗有效量的单独或与肝素组合的FGF-2。 效益的幅度和持续时间是意想不到的; 另外有利于IV路线是意想不到的。

    Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
    5.
    发明申请
    Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes 审中-公开
    使用维生素D化合物治疗骨髓增生异常综合征的方法

    公开(公告)号：US20050101576A1

    公开(公告)日：2005-05-12

    申请号：US10841820

    申请日：2004-05-10

    申请人： Martha Whitehouse ,  John Curd

    发明人： Martha Whitehouse ,  John Curd

    IPC分类号： A61K31/59 ,  A61K45/06

    CPC分类号： A61K45/06 ,  A61K31/59 ,  A61K2300/00

    摘要： Methods of treating MDS, or ameliorating a symptom thereof, are disclosed. Specific methods encompass the administration of one or more vitamin D compounds, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more additional active agents. Other methods include intermittent administration of a high dose of one or more vitamin D compounds, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more additional active agents. Such intermittent administration allows high doses of the vitamin D compounds to be administered while minimizing or eliminating hypercalcemia.

    摘要翻译： 公开了治疗MDS或改善其症状的方法。 具体方法包括单独或与一种或多种另外的活性剂组合施用一种或多种维生素D化合物或其药学上可接受的盐，溶剂合物，水合物，立体异构体，包合物或前药。 其它方法包括单独或与一种或多种另外的活性剂组合地间歇施用高剂量的一种或多种维生素D化合物或其药学上可接受的盐，溶剂合物，水合物，立体异构体，包合物或前药。 这种间歇施用允许施用高剂量的维生素D化合物，同时最小化或消除高钙血症。

    Prevention of Arterial Restenosis with Active Vitamin D Compounds
    6.
    发明申请
    Prevention of Arterial Restenosis with Active Vitamin D Compounds 审中-公开
    用活性维生素D化合物预防动脉再狭窄

    公开(公告)号：US20070148205A1

    公开(公告)日：2007-06-28

    申请号：US11614803

    申请日：2006-12-21

    申请人： Martha Whitehouse ,  Bradford Goodwin

    发明人： Martha Whitehouse ,  Bradford Goodwin

    IPC分类号： A61K31/59 ,  A61F2/02

    CPC分类号： A61K31/715 ,  A61K9/1075 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/59 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to a method for preventing, treating, or ameliorating arterial restenosis after angioplasty in an animal by administering to the animal active vitamin D compounds. The invention further relates to a method for preventing, treating, or ameliorating restenosis after angioplasty in an animal by administering to the animal active vitamin D compounds in combination with other therapeutic agents. A further aspect of the invention is a method for preventing, treating, or ameliorating stenosis within and/or around an arterial bypass graft in an animal comprising administering to the animal an active vitamin D compound.

    摘要翻译： 本发明涉及通过向动物施用活性维生素D化合物来预防，改善动物血管成形术后的动脉再狭窄的方法。 本发明进一步涉及一种通过向动物施用活性维生素D化合物与其它治疗剂组合来预防，改善或改善动物血管成形术后的再狭窄的方法。 本发明的另一方面是一种用于预防，治疗或改善动物中的动脉旁路移植物内和/或周围的狭窄的方法，包括向所述动物施用活性维生素D化合物。

    Prevention of arterial restenosis with active vitamin d compounds
    7.
    发明申请
    Prevention of arterial restenosis with active vitamin d compounds 审中-公开
    用活性维生素D化合物预防动脉再狭窄

    公开(公告)号：US20070142339A1

    公开(公告)日：2007-06-21

    申请号：US10589435

    申请日：2005-05-10

    申请人： Martha Whitehouse ,  Bradford Goodwin

    发明人： Martha Whitehouse ,  Bradford Goodwin

    IPC分类号： A61K31/59

    CPC分类号： A61K31/715 ,  A61K9/1075 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/59 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to a method for preventing, treating, or ameliorating arterial restenosis after angioplasty in an animal by administering to the animal active vitamin D compounds. The invention further relates to a method for preventing, treating, or ameliorating restenosis after angioplasty in an animal by administering to the animal active vitamin D compounds in combination with other therapeutic agents. A further aspect of the invention is a method for preventing, treating, or ameliorating stenosis within and/or around an arterial bypass graft in an animal comprising administering to the animal an active vitamin D compound.

    摘要翻译： 本发明涉及通过向动物施用活性维生素D化合物来预防，改善动物血管成形术后的动脉再狭窄的方法。 本发明进一步涉及一种通过向动物施用活性维生素D化合物与其它治疗剂组合来预防，改善或改善动物血管成形术后的再狭窄的方法。 本发明的另一方面是一种用于预防，治疗或改善动物中的动脉旁路移植物内和/或周围的狭窄的方法，包括向所述动物施用活性维生素D化合物。

    Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
    8.
    发明申请
    Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes 审中-公开
    使用维生素D化合物治疗骨髓增生异常综合征的方法

    公开(公告)号：US20070027120A1

    公开(公告)日：2007-02-01

    申请号：US11516776

    申请日：2006-09-07

    申请人： Martha Whitehouse ,  John Curd

    发明人： Martha Whitehouse ,  John Curd

    IPC分类号： A61K31/59

    CPC分类号： A61K45/06 ,  A61K31/59 ,  A61K2300/00

    摘要： Methods of treating MDS, or ameliorating a symptom thereof, are disclosed. Specific methods encompass the administration of one or more vitamin D compounds, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more additional active agents. Other methods include intermittent administration of a high dose of one or more vitamin D compounds, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more additional active agents. Such intermittent administration allows high doses of the vitamin D compounds to be administered while minimizing or eliminating hypercalcemia.

    摘要翻译： 公开了治疗MDS或改善其症状的方法。 具体方法包括单独或与一种或多种另外的活性剂组合施用一种或多种维生素D化合物或其药学上可接受的盐，溶剂合物，水合物，立体异构体，包合物或前药。 其它方法包括单独或与一种或多种另外的活性剂组合地间歇施用高剂量的一种或多种维生素D化合物或其药学上可接受的盐，溶剂合物，水合物，立体异构体，包合物或前药。 这种间歇给药允许施用高剂量的维生素D化合物，同时最小化或消除高钙血症。

    METHODS AND COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL ARTERY DISEASE
    9.
    发明申请
    METHODS AND COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL ARTERY DISEASE 失效
    用于治疗外周动脉疾病的方法和组合物

    公开(公告)号：US20070135348A1

    公开(公告)日：2007-06-14

    申请号：US11671382

    申请日：2007-02-05

    申请人： Martha Whitehouse

    发明人： Martha Whitehouse

    IPC分类号： A61K38/17

    CPC分类号： C07K14/50 ,  A61K38/1825 ,  A61K2300/00

    摘要： Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective amount of FGF-2 and a pharmaceutically acceptable carrier are also provided. The methods of the invention to treat peripheral artery disease and claudication comprise administering at least a single dose of a pharmaceutical composition comprising the FGF, such as FGF-2, via intra-arterial, intravenous, or intramuscular infusion to the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.

    摘要翻译： 提供了治疗患者外周动脉疾病的组合物和方法。 组合物包含重组成纤维细胞生长因子-2。 以治疗有效量施用成纤维细胞生长因子如FGF-2，以治疗或预防外周动脉疾病，包括跛行和严重肢体缺血。 还提供了包含治疗有效量的FGF-2和药学上可接受的载体的药物组合物。 本发明治疗外周动脉疾病和跛行的方法包括通过动脉内，静脉内或肌肉内输注至少单一剂量的包含FGF的药物组合物，例如FGF-2。 已经认识到，多次给药可能导致增加的益处，包括间歇给药。